Redeye: Fluoguide Q2 2024 - Following the plan
Redeye comments on Fluoguide’s Q2 2024 report, following its recent cSEK60m directed share issue that came at shareholder-friendly terms. We will closely watch FG001’s progression in clinical development and business development news in coming quarters. We do some housekeeping in our estimates and valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/